234
Participants
Start Date
February 29, 2012
Primary Completion Date
January 31, 2014
Study Completion Date
February 28, 2015
Sorafenib (Nexavar, BAY43-9006)
Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
Many Locations
Lead Sponsor
Bayer
INDUSTRY